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Abstract
Background: Carbapenem resistance in Klebsiella pneumoniae is of significant public health concern and recently
spread across several countries. We investigated the extent of carbapenem non-susceptibility in K. pneumoniae
isolates in Germany.
Methods: We analysed 2011–2016 data from the German Antimicrobial Resistance Surveillance (ARS) System, which
contains routine data of antimicrobial susceptibility testing from voluntarily participating German laboratories. Klebsiella
pneumoniae isolates tested resistant or intermediate against an antibiotic were classified as non-susceptible.
Results: We included 154,734 isolates from 655 hospitals in the analysis. Carbapenem non-susceptibility in K. pneumoniae
isolates was low in Germany 0.63% (95% CI 0.51–0.76%). However, in continuously participating hospitals the number
of K. pneumoniae isolates almost doubled and we found evidence for a slowly increasing trend for non-susceptibility
(OR = 1.20 per year, 95% CI 1.09–1.33, p < 0.001). Carbapenem non-susceptibility was highest among isolates from patients
aged 20–39 in men but not in women. Moreover, carbapenem non-susceptibility was more frequently reported for
isolates from tertiary care, specialist care, and prevention and rehabilitation care hospitals as well as from intensive care
units. Co-resistance of carbapenem non-susceptible isolates against antibiotics such as tigecycline, gentamicin, and
co-trimoxazole was common. Co-resistance against colistin was 13.3% (95% CI 9.8–17.9%) in carbapenem non-susceptible
isolates.
Conclusion: Carbapenem non-susceptibility in K. pneumoniae isolates in Germany is still low. However, it is slowly
increasing and in the light of the strong increase of K. pneumoniae isolates over the last year this poses a significant
challenge to public health. Continued surveillance to closely monitor trends as well as infection control and antibiotic
stewardship activities are necessary to preserve treatment options.
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Background
Klebsiella (K.) pneumoniae is a gram negative pathogen
in the family of Enterobacteriaceae. It is able to acquire
a wide array of antimicrobial resistance (AMR) genes
and can cause severe healthcare- associated infections
[1, 2]. Infections with carbapenem non-susceptible K. pneu-
moniae are associated with higher mortality and the World
Health Organization classified carbapenem-resistant K. pneu-
moniae as a critical priority pathogen for research and devel-
opment [3, 4]. Carbapenem resistance has been emerging
world-wide over the last years with local differences in fre-
quency and mechanisms of resistance [1]. The prevalence of
carbapenem non-susceptible K. pneumoniae strongly in-
creased in countries of Southern Europe such as Greece and
Italy [5]. Germany has experienced local outbreaks of
carbapenem-resistant K. pneumoniae and other resistant En-
terobacteriaceae [6, 7]. The German National Reference
Centre for multidrug-resistant gram-negative bacteria ana-
lyses carbapenem non-susceptible K. pneumoniae strains that
are submitted for further analysis and confirmation. In a re-
cent analysis, carbapenemases could be identified in 50,9% of
carbapenem-resistant K. pneumoniae isolates with OXA-48
being the most prevalent [8]. In a recent study in a German
academic tertiary care centre, OXA-48 was detected in 19 of
28 carbapenem-resistant K. pneumoniae isolates [9].
A pivotal element in the prevention and control of
carbapenem-resistant K. pneumoniae is the regular and on-
going surveillance of colonizations and infections in order
to inform infection control measures in hospitals [10].
The Antimicrobial Resistance Surveillance (ARS) is the
national surveillance system for AMR in Germany [11].
Since 2008, microbiological laboratories across Germany
voluntarily participate and submit data from routine anti-
microbial susceptibility testing to ARS. AMR data for
selected pathogens are accessible on the ARS website
(https://ars.rki.de). In addition, the surveillance system con-
tributes data to the European Antimicrobial Resistance
Surveillance Network (EARS-Net) and to the Global Anti-
microbial Resistance Surveillance System (GLASS) at the
World Health Organization [5].
In 2016, a national statutory surveillance system for car-
bapenem non-susceptibility was implemented in Germany.
However, information on changes in carbapenem resistance
over the recent years is scarce. The objective of our study
was to analyse trends and risk-factors for carbapenem
non-susceptibility of K. pneumoniae isolates in Germany as
well as co-resistance of carbapenem non-susceptible iso-
lates to other commonly used antibiotics.
Methods
Study design and data source
We undertook an observational cross-sectional study to
analyse carbapenem non-susceptibility of K. pneumoniae
isolates in hospitals in Germany.
Data on antimicrobial susceptibility testing are ob-
tained from ARS. Participating laboratories share their
data on routine antimicrobial susceptibility testing
(AST) of microbiological samples from hospitals and
medical practices [11]. Participation is voluntary for the
laboratories and can change over time. The sample of
hospitals and medical practices providing data to ARS is
organised by laboratory clusters. The geographical distri-
bution of the hospitals contributing data to the study is
shown in Additional file 1: Appendix S2. The identity of
the hospitals and medical practices is kept confidential.
Data on patients is anonymised.
The laboratories identify bacteria from specimens sent
in from hospitals or medical practices and determine the
zone diameters or minimum inhibitory concentrations
(MIC) of routinely used antibiotics (e.g. with microdilu-
tion, gradient or disk diffusion). Based on international
guidelines (e.g. by the European Committee on Anti-
microbial Susceptibility Testing (EUCAST)), the zone
diameter or MIC are used for the interpretative results
“susceptible” (S), “intermediate” (I), or “resistant” (R)
against the tested antibiotic.
All participating laboratories are accredited to perform
pathogen identification and antimicrobial susceptibility
testing. Data are checked for plausibility during the data
transmission process and are validated by the laborator-
ies annually for completeness and consistency.
Outcomes and covariates
The main outcome of the study is the proportion of car-
bapenem non-susceptible K. pneumoniae isolates in rela-
tion to all K. pneumoniae isolates tested for carbapenem
resistance. An isolate is considered non-susceptible
against an antibiotic if the susceptibility test results are
interpreted as “resistant” (R) or “intermediate” (I). Age
was converted into a categorical variable for the analysis
(< 1, 1–19, 20–39, 40–49, 50–59, 60–69, 70–79, and 80+
years). The specimen types were grouped as follows:
swabs (swabs from eye, nose, throat, ear, tongue, and
urogenital sites as well as intraoperative swabs and
other/unspecified swabs), blood (blood cultures), punc-
ture (tissue biopsy, cerebrospinal fluid, and aspirate from
pleural cavity, abscess, ascites, or joint puncture, other
punctures), urine (urine samples), wound (swabs from
wounds and abscesses), respiratory (bronchial lavage,
bronchial secretions, sputum, tracheal secretion, other
respiratory samples), other (dialysate, ejaculate, cathe-
ters, other). To analyse for seasonality, a categorical vari-
able was created according to the month in which the
isolate was obtained: January – March, April – June, July –
September, October – December. The geographic regions
were grouped as follows: Northwest (Bremen, Hamburg,
Lower Saxony, Schleswig-Holstein), West (North
Rhine-Westphalia), Southwest (Baden-Wuerttemberg,
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Hesse, Rhineland-Palatinate, Saarland), Southeast (Bavaria,
Saxony, Thuringia), and Northeast (Berlin, Brandenburg,
Mecklenburg-West Pomerania, Saxony-Anhalt). Several
variables on the county level of the hospital were also in-
cluded in the analysis: counties were divided into “rural” or
“city” based on a list from the Federal Agency for Cartog-
raphy and Geodesy [12, 13]. Moreover, the social
deprivation index per county was derived from the German
Index of Socioeconomic Deprivation (GISD) [14, 15]. The
GISD uses nine indicators from publicly available adminis-
trative datasets. It is based on factor analysis for indexing
and weighting of the indicators to the three latent dimen-
sions education, occupation and income. For the analysis, a
categorical variable was created dividing the counties by so-
cial deprivation index into quintiles with 1 indicating the
lowest deprivation and 5 the highest. In addition, the dens-
ity of hospital beds per 10.000 inhabitants was also included
on a county level. For the analysis a categorical variable was
created dividing the counties by hospital bed densities into
quartiles.
Analysed risk factors include age and sex of the pa-
tient, hospital care level (Secondary Care, Tertiary Care,
Specialist Care, Prevention and Rehabilitation Care,
other), type of care (intensive, normal hospital ward,
other), clinical speciality (surgery and related, internal
medicine, other), specimen type, region, county type
(rural, city), social deprivation index of the county where
the hospital is located, hospital beds per 10.000 inhabi-
tants in the county where the hospital is located as well
as year and quarter when the isolate was obtained.
In- and exclusion criteria of K. pneumoniae isolates
In the analysis, we focused on materials that are most
likely derived from clinical samples, so isolates labelled
as screening samples, anal swabs, and stool samples
were excluded. We excluded isolates without susceptibil-
ity testing. In order to avoid bias from repeated testing,
we only included the first isolate per patient per quarter
in the analysis irrespective of the specimen type. If sev-
eral isolates from one patient were tested on the same
day we selected the most relevant isolate for the analysis
according to this priority: isolate tested non-susceptible
against at least one carbapenem > isolate tested against
at least one carbapenem > isolate not tested against at
least one carbapenem.
Statistical analysis
The distribution of baseline characteristics of the K.
pneumoniae isolates was analysed using percentages and
95% confidence intervals (95% CI) for categorical vari-
ables accounting for clustering on the hospital level.
Continuous variables were analysed as means with
standard deviations if normally distributed and as
median with interquartile ranges if non-normally
distributed.
Carbapenem non-susceptibility was defined as the pro-
portion of non-susceptible isolates in relation to all
tested isolates in the analysis and expressed in percent-
age and 95% confidence intervals accounting for cluster-
ing on the hospital level. An isolate was considered
non-susceptible to at least one carbapenem if it was
tested as intermediate or resistant against meropenem,
imipenem, or ertapenem.
Risk factors for carbapenem non-susceptibility were
analysed using univariable and multivariable multilevel
(hierarchical) mixed-effects logistic regression models
with random intercepts, accounting for clustering on the
county and hospital level. Mixed models allow calculat-
ing intraclass correlation coefficients for the random in-
tercepts, to quantify variance on different levels [16].
P-values were calculated using Wald tests. For the multi-
variable model, year, quarter, age and sex of patient, hos-
pital care level, type of care, clinical speciality, specimen
type, region, county type, county deprivation index, and
hospital beds per 10,000 inhabitants were included. Iso-
lates with missing data in any of these variables were not
included in the uni- and multivariable regression models
(full case analysis).
For the analysis of carbapenem non-susceptibility over
time, a univariable multilevel (hierarchical) mixed-effects
logistic regression model was calculated with year as a
continuous variable. Only isolates from hospitals that
continuously contributed data from 2011 to 2016 were
included in the analysis. The p-value was derived from a
Wald test.
Sensitivity analyses
Not all isolates have been tested for resistance against all
three carbapenems (meropenem, imipenem, and ertape-
nem) and we conducted a sensitivity analysis restricted to
isolates that were tested against all three carbapenems.
Differences in EUCAST and CLSI breakpoints might
lead to different interpretations of carbapenem
non-susceptibility. Consequently, in some cases an isolate
might have been categorized as “sensitive” according to
one standard and as “intermediate” (i.e. non-susceptible)
according to the other standard. Since the use of standards
changes over time, this could have affected our results
over time. To address this issue, we performed sensitivity
analyses for changes in carbapenem non-susceptibility
over time: 1) restricted to isolates evaluated according to
EUCAST since this is the most commonly used standard
in our surveillance data; 2) excluding isolates categorized
as “intermediate” to one or more carbapenems and not
“resistant” to any carbapenem because for some isolates
the classification as “sensitive” or “intermediate” might de-
pend on the standard used.
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Resistance against some antibiotics is not routinely
tested (e.g. colistin), but only when resistance against
other antibiotics is found. Since this can introduce bias
into the analysis, we conducted a sensitivity analysis for
these antibiotics by restricting the analysis to isolates
from laboratories that routinely test ≥90% of all isolates
against the respective antibiotic.
Results
Of the 394,637 K. pneumoniae isolates in the database
we excluded screening isolates, isolates without anti-
microbial testing, repeated isolates of the same patient
within one quarter, and isolates from outpatients. We in-
cluded 154,734 isolates between 2011 and 2016 from
655 hospitals in the analysis (Fig. 1).
The median period of data availability per hospital was
2.0 years (IQR: 1.7–4.0 years). Out of all hospitals, 96
had continuous participation in our surveillance system
between 2011 and 2016 (45,995 isolates). Hospitals con-
tributing data to the analysis were distributed across
Germany with clusters in Schleswig-Holstein, North
Rhine-Westphalia, and Baden-Wuerttemberg (Add-
itional file 1: Appendix S2). Over time more hospitals
contributed data and the number of isolates strongly in-
creased (Additional file 1: Appendix S3). Interestingly,
the number of isolates from continuously participating
hospitals almost doubled. Most participating hospitals
and included isolates were from the western region in
Germany. Further information on the distribution of iso-
lates across subgroups can be found in Additional file 1:
Appendices S3 and S4.
Antimicrobial susceptibility testing results were inter-
preted according to guidelines from the EUCAST for
most isolates (76.2%). Other interpretation guidelines
used were from the Clinical & Laboratory Standards In-
stitute (CLSI, 15.4%), the German Institute for
Standardization (DIN, 7.2%), or no information on inter-
pretation guidelines was given (1.1%). Interpretation of
the results according to EUCAST guidelines strongly in-
creased over time (Additional file 1: Appendix S5).
Out of the 154,734 K. pneumoniae isolates, 99.9% were
tested against at least one carbapenem (Table 1).
Fig. 1 Selection of K. pneumoniae isolates from ARS database for the analysis, 2011–2016
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The proportion of isolates non-susceptible against at
least one carbapenem was 0.63% (95% CI 0.51–0.76%). In
detail, 0.11% (95% CI 0.08–0.13%) of the isolates were
tested intermediate against at least one carbapenem and
0.52% (95% CI 0.42–0.64%) were tested resistant. Almost
all isolates were tested against meropenem and imipenem,
whereas susceptibility against ertapenem was tested in
only about a third of the isolates. The proportion of
non-susceptible isolates was higher for ertapenem than
meropenem or imipenem. A sensitivity analysis restricted
to isolates tested against all three carbapenems yielded
comparable results (Additional file 1: Appendix S6).
Isolates found non-susceptible to meropenem or imi-
penem were often non-susceptible against the two other
carbapenems as well (Table 2).
Interestingly, only about half of the isolates tested
non-susceptible against ertapenem were also found to be
non-susceptible against meropenem or imipenem. A
sensitivity analysis restricted to isolates that had been
tested against all three carbapenems yielded similar re-
sults (Additional file 1: Appendix S7). In addition, we
found that out of the 501 isolates tested non-susceptible
against both imipenem and meropenem, 139 (27.7%)
were tested as intermediate against one or both of these
substances.
Non-susceptibility of isolates against at least one car-
bapenem increased from 0.35% in 2011 to 0.78% in 2016
(Table 3).
Since the number of the participating hospitals
changes over time, we restricted the analysis to 96 hospi-
tals that continuously contributed data to the analyses
between 2011 and 2016. In these hospitals carbapenem
non-susceptibility appears to be stable until 2013 and
then increased over the following years. We found evi-
dence for an increasing trend of carbapenem
non-susceptibility in the continuously participating hos-
pitals (OR = 1.20 per year, 95% CI 1.09–1.33, p < 0.001).
The sensitivity analyses 1) restricted to isolates evaluated
according to EUCAST and 2) excluding isolates labelled
as “intermediate” to one or more carbapenems and not
“resistant” to any carbapenem yielded similar results
(Additional file 1: Appendix S8).
In uni- and multivariable analyses for risk factors asso-
ciated with carbapenem non-susceptibility, we could ob-
serve that isolates collected from men were more likely
to be non-susceptible against at least one carbapenem
than isolates from women (Table 4 and Additional file 1:
Appendix S9).
Isolates from tertiary care, specialist care, and preven-
tion and rehabilitation care hospitals were more likely to
be non-susceptible against at least one carbapenem
(Table 4). In addition, isolates from patients in intensive
care units were also associated with a greater risk of car-
bapenem non-susceptibility. Compared to isolates from
urine cultures, isolates from swabs, wounds, and other
materials also were more likely to be non-susceptible.
We found some evidence that isolates from the region
“West” had the highest risk of non-susceptibility against
at least one carbapenem in multivariable analyses. We
found no association of quarter, clinical speciality,
county type, social deprivation index, and hospital beds
per 10,000 inhabitants with the outcome.




tested (% of all isolates)
Isolates tested “susceptible”
(% with 95% CI)a
Isolates tested “intermediate”
(% with 95% CI)a
Isolates tested “resistant”
(% with 95% CI)a
Isolates tested
“non-susceptible”
(% with 95% CI)a
Meropenem 150,746 (97.4%) 99.58% (99.49, 99.65%) 0.09% (0.07, 0.12%) 0.33% (0.27, 0.40%) 0.42%
(0.35, 0.51%)
Imipenem 150,114 (97.0%) 99.62% (99.54, 99.69%) 0.11% (0.09, 0.14%) 0.27% (0.22, 0.34%) 0.38%
(0.31, 0.46%)




154,524 (99.9%) 99.37% (99.24, 99.49%) 0.11% (0.08, 0.13%) 0.52% (0.42, 0.64%) 0.63%
(0.51, 0.76%)
a 95% CI calculated accounting for clustering on hospital level
bMeropenem, imipenem or ertapenem
Table 2 Cross-resistance of K. pneumoniae isolates non-susceptible against one carbapenem to other tested carbapenems
Additional non-susceptibility (R + I) against
Non-susceptibility (R + I) against Meropenem Imipenem Ertapenem
Meropenem (n = 634) – 501/619 (80.9%) 299/314 (95.2%)
Imipenem (n = 569) 501/562 (89.1%) – 252/272 (92.6%)
Ertapenem (n = 596) 252/591 (42.6%) 299/590 (50.7%) –
R resistant, I intermediate
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In the multivariable hierarchical logistical regression
model accounting for clustering between counties and
hospitals, the intraclass cluster coefficient for the vari-
ance of carbapenem non-susceptibility between counties
was 5.9% and between hospitals 11.8%. Overall, 17.8% of
the variance observed was attributable to clustering by
county and hospital.
When analysed according to age groups, isolates derived
from patients 20–39 years had the highest proportion of
non-susceptible isolates (1.17, 95%CI 0.79–1.71%)
(Additional file 1: Appendix S9). A stratification of carba-
penem non-susceptibility across age groups according to
sex showed that the increase in non-susceptibility in the
younger age groups affected only isolates from men
whereas isolates from women had a decreased chance for
carbapenem non-susceptibility in both uni- and multivari-
able analyses (p for interaction < 0.001) (Fig. 2, Additional
file 1: Appendix S10). Moreover, this pattern remained un-
changed in analyses excluding isolates from gynaecology /
obstetric wards or excluding isolates from urine samples
(Additional file 1: Appendix S10).
For the 966 isolates non-susceptible to at least one
carbapenem, we investigated co-resistance to other anti-
biotics (Table 5).
Non-susceptibility against penicillin/beta-lactamase in-
hibitor combinations, 3rd generation cephalosporins,
fluoroquinolones, and nitrofurantoin was high. For tige-
cycline, fosfomycin, gentamicin, and co-trimoxazole
non-susceptibility was found in about half of the isolates.
Non-susceptibility was lowest for colistin / polymyxins
with 13.3% (95% CI 9.8–17.9%). To investigate selective
testing, we restricted the analyses to isolates from labora-
tories that tested at least 90% of their isolates against the
respective antibiotic. The proportion of non-susceptible
isolates remained similar to the overall analysis. Out of the
966 isolates non-susceptible to at least one carbapenem,
143 were tested against all antibiotics listed in Table 5
(14.8%). Two of those isolates were tested non-susceptible
against all the above mentioned antibiotics, indicating
pan-resistant K. pneumoniae isolates. In addition, we
found 119 isolates that were potentially pan-resistant, i.e.
they were tested non-susceptible to the above mentioned
antibiotics where investigated, but susceptibility testing re-
sults were not available for all these antibiotics.
Discussion
In this study using routinely collected data on antimicrobial
susceptibility testing we found that carbapenem
non-susceptibility in K. pneumoniae isolates was 0.63%
(95% CI 0.51–0.76%) and slowly increasing (OR = 1.20 per
year, 95% CI 1.09–1.33, p < 0.001). Carbapenem
non-susceptibility increased across younger age groups in
isolates from men but not from women. Co-resistance
against antibiotics of last resort for the treatment of patients
with multi-drug resistant bacterial infections was common.
Carbapenem resistance has increased strongly over the
last years in some regions, e.g. the United States, China,
and southern European countries [5, 17, 18]. In contrast,
the proportion of carbapenem non-susceptible isolates
in Germany is still low and only slowly increasing. How-
ever, we found that the absolute numbers of K. pneumo-
niae isolates from continuously participating hospitals
almost doubled from 2011 to 2016, which indicates a
growing public health burden concerning K. pneumoniae
in general and carbapenem non-susceptible K. pneumo-
niae in particular.
The absolute number of K. pneumoniae isolates was
highest in the older age groups, which is in accordance
with the literature [19, 20]. However, upon stratification
by age and sex, it is striking that the proportion of car-
bapenem non-susceptibility is highest in isolates from
younger male patients (ages 20–39) and lowest in female
patients of the same age groups. Since we do not have
further patient-based information available, we can only
speculate on the reasons. This effect might be related to
differences in patient-based risk factors between men
and women at this age. Since we analysed only isolates
from hospitals, it is possible that many women in this
age group might enter the hospital for child birth while
they have a good health status and few risk factors for
Table 3 Non-susceptibility of K. pneumoniae isolates against at least one carbapenem
Percentage non-susceptible (R + I) against at least one carbapenema (95%CI)b
Year Number of hospitals All hospitals Continuously participating hospitals (n = 96)
2011 180 0.35% (0.18%; 0.69%) 0.30% (0.17%; 0.51%)
2012 306 0.46% (0.31%; 0.68%) 0.27% (0.17%; 0.41%)
2013 363 0.49% (0.36%; 0.67%) 0.28% (0.18%; 0.45%)
2014 266 0.74% (0.53%; 1.04%) 0.78% (0.46%; 1.33%)
2015 372 0.66% (0.54%; 0.80%) 0.56% (0.35%; 0.89%)
2016 418 0.78% (0.58%; 1.06%) 0.53% (0.35%; 0.81%)
R resistant, I intermediate, CI confidence interval
aMeropenem, imipenem or ertapenem
b95% CI calculated accounting for clustering on hospital level
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Table 4 Analysis of risk factors associated with carbapenem non-susceptibility of K. pneumoniae isolates
Univariable analysis of risk factors
associated with carbapenem
non-susceptibility
Multivariable analysis of risk
factors associated with
carbapenem non-susceptibility
OR (95% CI)a p-valueb OR (95% CI)c p-valueb
Year
2011 1 – 1 –
2012 1.00 (0.64, 1.57) 0.994 0.99 (0.63, 1.56) 0.964
2013 1.29 (0.84, 1.99) 0.239 1.30 (0.85, 2.01) 0.229
2014 1.78 (1.16, 2.75) 0.009 1.84 (1.19, 2.84) 0.006
2015 1.87 (1.23, 2.86) 0.004 1.99 (1.29, 3.05) 0.002
2016 2.00 (1.32, 3.05) 0.001 2.10 (1.38, 3.22) 0.001
Quarter
Jan - Mar 1 – 1 –
Apr - Jun 1.14 (0.93, 1.40) 0.217 1.13 (0.92, 1.39) 0.248
Jul - Sept 1.07 (0.87, 1.31) 0.515 1.06 (0.87, 1.30) 0.553
Oct - Dec 1.05 (0.86, 1.30) 0.618 1.07 (0.87, 1.31) 0.542
Age (years)
< 1 0.49 (0.21, 1.11) 0.089 0.26 (0.11, 0.61) 0.002
1–19 2.28 (1.45, 3.58) < 0.001 1.67 (1.06, 2.66) 0.029
20–39 2.87 (2.17, 3.79) < 0.001 2.38 (1.78, 3.18) < 0.001
40–49 1.88 (1.33, 2.64) < 0.001 1.49 (1.05, 2.10) 0.025
50–59 2.10 (1.63, 2.70) < 0.001 1.62 (1.26, 2.10) < 0.001
60–69 1.73 (1.37, 2.18) < 0.001 1.35 (1.06, 1.71) 0.013
70–79 1.57 (1.28, 1.94) < 0.001 1.33 (1.08, 1.65) 0.007
80+ 1 – 1 –
Sex
Male 1.81 (1.57, 2.10) < 0.001 1.57 (1.35, 1.83) < 0.001
Female 1 – 1 –
Hospital Care Level
Secondary Care 1 – 1 –
Tertiary Care 3.52 (2.02, 6.11) < 0.001 2.68 (1.55, 4.66) < 0.001
Specialist Care 2.16 (1.39, 3.37) 0.001 2.44 (1.57, 3.78) < 0.001
Prevention and Rehabilitation Care 1.92 (0.93, 3.98) 0.078 2.22 (1.09, 4.52) 0.028
Other 0.91 (0.26, 3.21) 0.886 1.03 (0.29, 3.61) 0.966
Type of care
Intensive care unit 2.58 (2.20, 3.03) < 0.001 2.37 (1.98, 2.84) < 0.001
Normal hospital ward 1 – 1 –
Other 1.96 (1.26, 3.06) 0.003 1.69 (1.08, 2.64) 0.022
Clinical specialty
Surgery and related 1.50 (1.24, 1.82) < 0.001 1.15 (0.94, 1.40) 0.176
Internal medicine 1 – 1 –
Other 1.50 (1.26, 1.78) < 0.001 0.98 (0.81, 1.18) 0.821
Sample type
Swabs 2.35 (1.94, 2.85) < 0.001 1.87 (1.53, 2.29) < 0.001
Blood culture 1.45 (1.01, 2.06) 0.043 1.08 (0.76, 1.56) 0.661
Puncture 1.46 (0.90, 2.37) 0.126 1.08 (0.66, 1.76) 0.769
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carbapenem non-susceptibility. Men of the same age
group, however, might potentially have more severe rea-
sons for being in the hospital and thus potentially ex-
hibit more risk factors to acquire carbapenem
non-susceptible strains. However, sensitivity analyses ex-
cluding isolates from potentially healthier patients (from
gynaecology / obstetric wards or from urine samples)
still showed the same pattern of non-susceptibility and
could not explain the observed disparity. Further studies
with clinical information are needed to investigate this
issue.
Other identified risk factors associated with carba-
penem non-susceptibility include isolates from tertiary
care, specialist care, and prevention and rehabilitation
care hospitals as well as from ICU wards. These findings
are in accordance with the literature [20–25] and can be
attributed to patients with severe co-morbidities and risk
factors for acquiring resistant bacteria. We did not find
an association with social deprivation status of the
county where the hospital is located and carbapenem
non-susceptibility even though social deprivation is asso-
ciated with poorer health outcomes. It would be interest-
ing to investigate the impact of social deprivation on the
patients’ level, which is, however, not available in our
surveillance data.
The findings of our study yield valuable information
for infection control practices. While measures accord-
ing to international guidelines including hand hygiene,
contact precautions, patient isolation and environmental
cleaning are recommended for all health institutions
dealing with carbapenem-resistant strains [10], our re-
sults highlight that carbapenem non-susceptible isolates
Table 4 Analysis of risk factors associated with carbapenem non-susceptibility of K. pneumoniae isolates (Continued)
Univariable analysis of risk factors
associated with carbapenem
non-susceptibility
Multivariable analysis of risk
factors associated with
carbapenem non-susceptibility
OR (95% CI)a p-valueb OR (95% CI)c p-valueb
Urine 1 – 1 –
Wound 1.90 (1.49, 2.41) < 0.001 1.45 (1.13, 1.87) 0.003
Respiratory 2.07 (1.69, 2.53) < 0.001 1.21 (0.97, 1.51) 0.093
Other 3.01 (1.98, 4.58) < 0.001 2.11 (1.37, 3.23) < 0.001
Region
Northwest 1 – 1 –
West 1.70 (0.93, 3.14) 0.087 1.73 (0.98, 3.06) 0.057
Southwest 1.03 (0.55, 1.93) 0.922 1.01 (0.55, 1.84) 0.983
Southeast 1.10 (0.55, 2.20) 0.783 0.89 (0.46, 1.71) 0.721
Northeast 1.57 (0.74, 3.33) 0.241 1.43 (0.69, 2.98) 0.336
County Type
Rural 1 – 1 –
City 1.34 (0.93, 1.92) 0.119 1.17 (0.74, 1.84) 0.508
Counties by Social Deprivation Index
1 (lowest deprivation) 1 – 1 –
2 1.29 (0.68, 2.44) 0.444 1.29 (0.70, 2.36) 0.412
3 0.96 (0.51, 1.82) 0.897 0.88 (0.47, 1.64) 0.687
4 0.84 (0.44, 1.61) 0.609 0.79 (0.42, 1.47) 0.452
5 (highest deprivation) 0.99 (0.53, 1.84) 0.971 0.91 (0.49, 1.69) 0.758
Hospital Beds per 10.000 inhabitants
8.2–57.2 1 – 1 –
57.3–71.5 0.96 (0.59, 1.56) 0.870 0.87 (0.53, 1.42) 0.577
71.6–90.9 0.82 (0.51, 1.33) 0.431 0.62 (0.36, 1.08) 0.093
91.0–219.0 1.49 (0.94, 2.36) 0.087 1.01 (0.58, 1.77) 0.969
Isolates from patients with missing values on the variables were not included in the analysis
CI confidence interval, OR odds ratio
aHierarchical Logistic Regression model accounting for clustering within counties and hospitals
bWald test
cHierarchical Logistic Regression model accounting for clustering within counties and hospitals adjusting for year, quarter age, sex, hospital care level, type of care,
clinical specialty, sample type, region, county type, social deprivation index, and hospital beds per 10,000 inhabitants
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were more common in Germany in highly specialized
hospitals and intensive care units. Thus, these types of
hospitals and hospital units should be especially vigilant
and need to implement effective surveillance and infec-
tion control measures.
Treatment options for infections with carbapenem
non-susceptible K. pneumoniae are very limited. While iso-
lates non-susceptible to imipenem or meropenem were
mostly non-susceptible to the other two carbapenems as
well, in contrast only about half of the isolates
non-susceptible to ertapenem showed non-susceptibility to
the other two carbapenems. Ertapenem being the more
sensitive parameter for carbapenemase producing isolates
has been described in the literature [26, 27]. This underlines
that Ertapenem non-susceptible isolates should be tested
for carbapenemases even when they are still susceptible to
meropenem and imipenem. Moreover, in about one third
of the isolates tested non-susceptible against imipenem or
meropenem we found intermediate susceptibility against
one or both substances, which would make them eligible
Fig. 2 Multivariable analysis for carbapenem non-susceptibility of K. pneumoniae isolates stratified by age and sex, Germany 2011–2016. Hierarchical
logistic regression accounting for county and hospital, Outcome: carbapenem non-susceptibility stratified by age and sex, adjusted for year, quarter,
hospital care level, type of care, clinical speciality, specimen type, region, county type, social deprivation index, and hospital beds per 10,000 inhabitants
Table 5 Co-resistance of carbapenem non-susceptible K. pneumoniae isolates (n = 966) against other antibiotics
Isolates from all laboratories Isolates from laboratories that routinely
test against the specified antibiotica
Tested against Included isolates Non-susceptible isolates,
% (95%CI)b
Included isolates Non-susceptible isolates,
% (95%CI)b
Ampicillin/ Sulbactam 871 93.0% (90.3, 95.0%) c c
Piperacillin/ Tazobactam 950 90.7% (87.4, 93.2%) c c
Ceftazidime 954 88.7% (85.8, 91.0%) c c
Cefotaxime 908 88.3% (85.0, 91.0%) c c
Polymyxin/ Colistin 435 13.3% (9.8, 17.9%) 214 14.0% (8.8, 21.7%)
Tigecycline 865 56.6% (51.0, 62.1%) 709 55.6% (49.1, 61.8%)
Fosfomycin 632 47.0% (40.6, 53.5%) 319 46.7% (36.2, 57.5%)
Gentamicin 960 57.8% (53.0, 62.4%) c c
Co-Trimoxazole 961 62.7% (57.6, 67.6%) c c
Ciprofloxacin 959 82.0% (78.4, 85.0%) c c
Nitrofurantoin 313 82.7% (76.3, 87.7%) 99 72.7% (60.0, 82.6%)
R resistant, I intermediate, CI confidence interval
aAnalysis restricted to laboratories that test > 90% of isolates against the specified antibiotic
b95% CI calculated accounting for clustering by hospital
cAntibiotic is routinely tested in all laboratories (> 90% of all isolates tested)
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for use in combination therapy. Penicillin/beta-lactamase
inhibitor combinations, 3rd generation cephalosporins,
fluoroquinolones and nitrofurantoin were not suitable
treatment options for most isolates owing to high propor-
tions of non-susceptibility. Less than half of the carba-
penem non-susceptible isolates were still susceptible to
tigecycline or gentamicin. This is lower than in previous
studies and highlights the clinical challenges of infections
with carbapenem-resistant K. pneumoniae [19, 20, 22, 28].
Non-susceptibility against colistin was observed in 13.3% of
the isolates, which is comparable to other studies. However,
recent publications question the reliability of routine testing
methods for colistin so that the observed result
should be interpreted with caution and validated in
the future [29, 30]. This is especially important since
treatment of carbapenem-resistant K. pneumoniae can
require combinations of two or three antibiotics often
including colistin [28, 31–33]. In this study, we found
only two isolates that were non-susceptible to all the
antibiotics analysed so that limited treatment options
remain for most isolates in this study. However, ef-
fective antibiotic stewardship measures should be im-
plemented to keep carbapenem-resistance low and to
preserve treatment options [34].
This study uses routine data from accredited labora-
tories and can base its estimates on isolates from 655
hospitals across the country. This is the first time a
study of this size has been conducted in Germany and
we are able to investigate even low proportions of carba-
penem non-susceptibility in K. pneumoniae with satis-
factory statistical precision. We included routine data
from about one third of all hospitals in Germany [35].
The sample of hospitals is reasonably large and the esti-
mates between a) descriptive analysis and b) regression
analysis adjusting for clustering by region and hospital
are comparable. Thus, we are confident that our analysis
yields valid results and do not expect a major influence
of selection bias.
We excluded screening isolates since these have a dif-
ferent probability of showing resistance than clinical iso-
lates. However, since we do not have any clinical patient
information, it is possible that some isolates, e.g. from
swabs or the respiratory tract, were also derived from
screening samples. Due to the study design it was not
possible to account for this.
Moreover, laboratories used different guidelines to inter-
pret their AST results (EUCAST, CLSI or DIN), which
could lead to differences in qualitative interpretation of
the results. Owing to those discrepancies, a small propor-
tion of isolates with values close to the breakpoints might
have been classified as “sensitive” according to one stand-
ard and “intermediate” (i.e. non-susceptible) according to
the other. Since the use of EUCAST increased over time,
this could have artificially influenced the trend analyses
over time. However, since the sensitivity analyses re-
stricted to EUCAST isolates or excluding isolates evalu-
ated as “intermediate” yielded similar results as the main
analysis, we do not expect this effect to have a substantial
impact on our study.
Conclusions
Carbapenem non-susceptibility in K. pneumoniae iso-
lates in Germany is still low but slowly increasing. Since
the overall number of tested K. pneumoniae isolates ap-
pears to increase as well, this highlights the growing
public health burden of carbapenem resistance in
Germany. Continued surveillance, implementation of ef-
fective infection prevention and control measures, and
sustained antibiotic stewardship efforts are necessary to
address these problems.
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